2025-02-26T07:30:51-07:00 2024-06-30 990 2023-07-01 201624945 XENOBE RESEARCH INSTITUTE XENO 8584013083 PO Box 3052 San Diego CA 921631052 James La Clair President 8584013083 2024-10-15 1 2023 2025-03-06 01:10:19Z X James J La Clair 10630 Queen Avenue La Mesa CA 91941 61315 0 X www.xenobe.org X 2004 CA Scientific Research. The Xenobe Research Institute conducts research on natural and synthetic small molecule therapeutics with the ultimate goal of discovering and ultimately translating new materials for clinical trials. 2 0 0 0 0 0 352250 61315 0 0 0 0 0 0 352250 61315 0 0 0 0 47645 64883 0 0 0 107127 82617 154772 147500 197478 -86185 314286 228101 0 0 314286 228101 The Xenobe Research Institute conducts research on natural and synthetic small molecule therapeutics with the ultimate goal of discovering and ultimately translating new materials for clinical trials. 0 0 32442 0 -32442 National Institutes of Health Grant R21NS128597. While well established as clinical targets, the lack of molecular probes to the large immunophilins continues to inhibit our ability to evaluate and drug them clinically. This program explores the development of a general platform to discover probes that target specific domains within a neurological protein. Using cyclophilin 40 (Cyp40), FK506-binding proteins FKBP51 and FKBP52, our team seeks to define critically needed reagents to understand the role of the `large immunophilin' family in neurological disease. We began studies on our recently funded R21 program and have reported signficance success within our initial year of funding.The revenue generated will be used for the latter half of the program. A two year award was provided within this funding period. These funds to cover salaries, research supplies, instrument time, and equipment access to complete these studies. 48663 36000 -12663 Varigen Biosciences / Terra Bioworks. Granted funding was provided to support small molecule isolation and structure elucidation efforts. These funds were used to cover research supplies, instrument time, and equipment access to complete these studies. Two publications were published: Pham NT, Alves J, Sargison FA, Cullum R, Wildenhain J, Fenical W, Butler MS, Mead DA, Duggan BM, Fitzgerald JR, La Clair JJ, Auer M. Nanoscaled Discovery of a Shunt Rifamycin from Salinispora arenicola Using a Three-Color GFP-Tagged Staphylococcus aureus Macrophage Infection Assay. ACS Infect Dis. 2023 Aug 11;9(8):1499-1507. Stankey RJ, Johnson D, Duggan BM, Mead DA, La Clair JJ. A Survey of Didemnin Depsipeptide Production in Tistrella. Mar Drugs. 2023 Jan 17;21(2):56. doi: 10.3390/md21020056. 13533 13500 -33 National Institutes of Health Grant R01CA236352 via a Salk Institute Sub-Award. Studies associated with sub-award associated with NIH grant R01CA236352 were conducted. These studies focused on developing methods for plant natural product production, isolation and structure elucidation. As well as the preparation of probes and synthetic materials. The remaining funds are being used to support the ongoing efforts towards this program. 11451 11815 363 Grant from Metabolon. Funds were provided to guide synthesis of an unknown natural product including providing spectroscopic services. Funds were used to sponsor lecture costs as well as conduct spectroscopic services. 11451 11815 363 106089 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 X 2 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 CA X X X James J La Clair 8584013083 PO Box 3052 San Diego CA 921631052 James J La Clair President 5 0 X X X X 44193 0 0 Manfred Auer Director 5 0 X X 0 0 0 44193 0 0 0 0 0 0 0 0 0 0 0 13500 47815 0 61315 0 0 0 0 0 0 0 61315 0 0 0 0 0 0 0 0 0 0 0 44193 22096 22097 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 20690 10345 10345 0 0 0 0 0 0 0 0 0 2482 0 2482 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4454 0 4454 0 0 0 0 0 0 0 0 0 0 0 0 0 10596 10596 0 0 0 0 0 0 11000 11000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Scientific Research 52052 52052 0 0 Shipping and Publications 2033 0 2033 0 0 0 0 0 147500 106089 41411 0 217611 131426 0 0 0 0 0 0 0 0 0 0 0 0 96675 96675 0 0 0 0 0 0 0 0 0 0 0 0 314286 228101 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 314286 228101 0 0 314286 228101 314286 228101 -86185 0 0 0 0 0 X 0 0 0 X 28600 77000 77500 352250 61315 596665 0 0 0 0 0 0 0 0 0 0 0 0 28600 77000 77500 352250 61315 596665 596665 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 596665 0 1 1 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Form 990, Header, Line B We have amended this return due to a change by the NIH in notice of award revision for NIH grant 1201624945A1. The original award was for 275,000 without indirect costs. After considerable negotiations, the grant awarded the IDC of 12/19/2024. Funds were not obtained during this funding period but in 2/2025 and will be reported correctly in this calendar year. We also were requested to revise our allocations in Part IX by the Department of Health and Human Services. Form 990, Part VI, Section B, Line 11b Copies are sent to all members of the organization Form 990, Part VI, Section B, Line 12c Quarterly reviews of the two members of the institute Form 990, Part VI, Section C, Line 19 Yes our documents are shared with the NIH and made public on our website We ammended the filing due to request from the Department of Health and Human Services in response to action from the National Institutes of Health. We did not properly represent direct and indirect (IDC) associated with an NIH grant.